Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):17–21. doi: 10.1128/aac.40.1.17

Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

L Aguilar 1, I P Balcabao 1, P Salvá 1, M Martín 1, J Costa 1, J Prieto 1, R Dal-ré 1
PMCID: PMC163049  PMID: 8787872

Abstract

Twelve adult males participated in a randomized crossover phase I clinical trial comparing serum bactericidal titers (SBTs), urine bactericidal titers (UBTs), and urine killing rates (UKRs) against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213, after the administration of single 400-mg doses of rufloxacin and norfloxacin at different times up to 72 h postdose. SBTs were significantly higher (P < 0.05) against E. coli from 8 to 48 h and against S. aureus from 4 to 24 h with rufloxacin. UBTs for E. coli were higher (P < 0.05) for norfloxacin at early sample times (0 to 8 h) but higher for rufloxacin (P < 0.05) at sample times from 16 h on for both E. coli and S. aureus. Similar UKRs were obtained for both quinolones for 0 to 2 h and 8 to 12 h, but the UKR was maintained for 72 h with rufloxacin. The high and sustained mean levels of rufloxacin in urine (> 35 micrograms/ml), median UBTs (> 32 for E. coli and 16 for S. aureus) and UKRs for E. coli suggest prolonged urine antibacterial activity (for at least 72 h) and its use as a single 400-mg dose in the treatment of uncomplicated cystitis.

Full Text

The Full Text of this article is available as a PDF (203.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguilar L., Esteban C., Frias J., Pérez-Balcabao I., Carcas A. J., Dal-Ré R. Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers. J Antimicrob Chemother. 1994 Jan;33(1):91–101. doi: 10.1093/jac/33.1.91. [DOI] [PubMed] [Google Scholar]
  2. Bergeron M. G., Bernier M., L'Ecuyer J. In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae. Infection. 1992 May-Jun;20(3):164–167. doi: 10.1007/BF01704612. [DOI] [PubMed] [Google Scholar]
  3. Craig W. A., Welling P. G. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1977 Jul-Aug;2(4):252–268. doi: 10.2165/00003088-197702040-00002. [DOI] [PubMed] [Google Scholar]
  4. Cruciani M., Monzillo V., Navarra A., Tinelli C., Concia E. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers. Drugs Exp Clin Res. 1988;14(8):533–537. [PubMed] [Google Scholar]
  5. Crumplin G. C., Smith J. T. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother. 1975 Sep;8(3):251–261. doi: 10.1128/aac.8.3.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Forrest A., Nix D. E., Ballow C. H., Goss T. F., Birmingham M. C., Schentag J. J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073–1081. doi: 10.1128/aac.37.5.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hooton T. M., Johnson C., Winter C., Kuwamura L., Rogers M. E., Roberts P. L., Stamm W. E. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob Agents Chemother. 1991 Jul;35(7):1479–1483. doi: 10.1128/aac.35.7.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Imbimbo B. P., Broccali G., Cesana M., Crema F., Attardo-Parrinello G. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob Agents Chemother. 1991 Feb;35(2):390–393. doi: 10.1128/aac.35.2.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Israel D., Gillum J. G., Turik M., Harvey K., Ford J., Dalton H., Towle M., Echols R., Heller A. H., Polk R. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1993 Oct;37(10):2193–2199. doi: 10.1128/aac.37.10.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Johnson J. R., Stamm W. E. Diagnosis and treatment of acute urinary tract infections. Infect Dis Clin North Am. 1987 Dec;1(4):773–791. [PubMed] [Google Scholar]
  11. Kisicki J. C., Griess R. S., Ott C. L., Cohen G. M., McCormack R. J., Troetel W. M., Imbimbo B. P. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrob Agents Chemother. 1992 Jun;36(6):1296–1301. doi: 10.1128/aac.36.6.1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klastersky J., Daneau D., Swings G., Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis. 1974 Feb;129(2):187–193. doi: 10.1093/infdis/129.2.187. [DOI] [PubMed] [Google Scholar]
  13. Kowalsky S. F., Echols R. M., McCormick E. M. Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria. J Antimicrob Chemother. 1990 May;25(5):767–775. doi: 10.1093/jac/25.5.767. [DOI] [PubMed] [Google Scholar]
  14. Leggett J. E., Wolz S. A., Craig W. A. Use of serum ultrafiltrate in the serum dilution test. J Infect Dis. 1989 Oct;160(4):616–623. doi: 10.1093/infdis/160.4.616. [DOI] [PubMed] [Google Scholar]
  15. Phillips I., Culebras E., Moreno F., Baquero F. Induction of the SOS response by new 4-quinolones. J Antimicrob Chemother. 1987 Nov;20(5):631–638. doi: 10.1093/jac/20.5.631. [DOI] [PubMed] [Google Scholar]
  16. Pien F. D., Williams R. D., Vosti K. L. Comparison of broth and human serum as the diluent in the serum bactericidal test. Antimicrob Agents Chemother. 1975 Jan;7(1):113–114. doi: 10.1128/aac.7.1.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ravizzola G., Pinsi G., Pirali F., Colombrita D., Foresti I., Peroni L., Turano A. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity. Drugs Exp Clin Res. 1989;15(1):11–15. [PubMed] [Google Scholar]
  18. Shumaker R. C. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986;17(3-4):331–348. doi: 10.3109/03602538608998295. [DOI] [PubMed] [Google Scholar]
  19. Stamey T. A., Fair W. R., Timothy M. M., Millar M. A., Mihara G., Lowery Y. C. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974 Nov 28;291(22):1159–1163. doi: 10.1056/NEJM197411282912204. [DOI] [PubMed] [Google Scholar]
  20. Stamm W. E., Hooton T. M. Management of urinary tract infections in adults. N Engl J Med. 1993 Oct 28;329(18):1328–1334. doi: 10.1056/NEJM199310283291808. [DOI] [PubMed] [Google Scholar]
  21. Stevens P. J. Bactericidal effect against Escherichia coli of nalidixic acid and four structurally related compounds. J Antimicrob Chemother. 1980 Jul;6(4):535–542. doi: 10.1093/jac/6.4.535. [DOI] [PubMed] [Google Scholar]
  22. Wise R., Andrews J. M., Matthews R., Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother. 1992 Jun;29(6):649–660. doi: 10.1093/jac/29.6.649. [DOI] [PubMed] [Google Scholar]
  23. Wise R., Johnson J., O'Sullivan N., Andrews J. M., Imbimbo B. P. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother. 1991 Dec;28(6):905–909. doi: 10.1093/jac/28.6.905. [DOI] [PubMed] [Google Scholar]
  24. Zeiler H. J., Beermann D., Wingender W., Förster D., Schacht P. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection. 1988;16 (Suppl 1):S19–S23. doi: 10.1007/BF01650502. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES